Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 574 Million USD | -24.87% |
| 2023 | 764 Million USD | 8.83% |
| 2022 | 702 Million USD | 24.69% |
| 2021 | 563 Million USD | 73.87% |
| 2020 | 323.8 Million USD | 25.89% |
| 2019 | 257.2 Million USD | 23.0% |
| 2018 | 209.1 Million USD | 13.09% |
| 2017 | 184.9 Million USD | 19.44% |
| 2016 | 154.8 Million USD | 16.48% |
| 2015 | 132.9 Million USD | -1.41% |
| 2014 | 134.8 Million USD | -1.39% |
| 2013 | 136.7 Million USD | 4.83% |
| 2012 | 130.4 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 811 Million USD | 6.15% |
| 2024 Q2 | 775 Million USD | -4.44% |
| 2024 FY | 574 Million USD | -24.87% |
| 2024 Q4 | 574 Million USD | -25.45% |
| 2024 Q3 | 770 Million USD | -0.65% |
| 2023 FY | 764 Million USD | 8.83% |
| 2023 Q3 | 744 Million USD | -11.53% |
| 2023 Q4 | 764 Million USD | 2.69% |
| 2023 Q2 | 841 Million USD | 11.69% |
| 2023 Q1 | 753 Million USD | 4.01% |
| 2022 Q2 | 709 Million USD | 8.58% |
| 2022 Q3 | 697 Million USD | -1.69% |
| 2022 FY | 702 Million USD | 24.69% |
| 2022 Q1 | 653 Million USD | 15.99% |
| 2022 Q4 | 724 Million USD | 3.87% |
| 2021 Q3 | 555.1 Million USD | 14.17% |
| 2021 FY | 563 Million USD | 73.87% |
| 2021 Q1 | 406.7 Million USD | 25.6% |
| 2021 Q2 | 486.2 Million USD | 19.55% |
| 2021 Q4 | 563 Million USD | 1.42% |
| 2020 Q3 | 320.3 Million USD | 24.0% |
| 2020 Q1 | 259.1 Million USD | 0.74% |
| 2020 Q2 | 258.3 Million USD | -0.31% |
| 2020 Q4 | 323.8 Million USD | 1.09% |
| 2020 FY | 323.8 Million USD | 25.89% |
| 2019 Q1 | 246.7 Million USD | 17.98% |
| 2019 FY | 257.2 Million USD | 23.0% |
| 2019 Q4 | 257.2 Million USD | 0.19% |
| 2019 Q3 | 256.7 Million USD | 4.43% |
| 2019 Q2 | 245.8 Million USD | -0.36% |
| 2018 Q3 | 235 Million USD | 4.86% |
| 2018 Q4 | 209.1 Million USD | -11.02% |
| 2018 FY | 209.1 Million USD | 13.09% |
| 2018 Q1 | 205.9 Million USD | 11.36% |
| 2018 Q2 | 224.1 Million USD | 8.84% |
| 2017 Q1 | 188.6 Million USD | 21.83% |
| 2017 FY | 184.9 Million USD | 19.44% |
| 2017 Q3 | 205.6 Million USD | 13.65% |
| 2017 Q4 | 184.9 Million USD | -10.07% |
| 2017 Q2 | 180.9 Million USD | -4.08% |
| 2016 FY | 154.8 Million USD | 16.48% |
| 2016 Q4 | 154.8 Million USD | -13.57% |
| 2016 Q3 | 179.1 Million USD | 5.04% |
| 2016 Q2 | 170.5 Million USD | 5.18% |
| 2016 Q1 | 162.1 Million USD | 21.97% |
| 2015 Q2 | 144.3 Million USD | 1.33% |
| 2015 Q1 | 142.4 Million USD | 5.64% |
| 2015 FY | 132.9 Million USD | -1.41% |
| 2015 Q4 | 132.9 Million USD | -13.48% |
| 2015 Q3 | 153.6 Million USD | 6.44% |
| 2014 Q2 | 152.6 Million USD | 5.1% |
| 2014 Q1 | 145.2 Million USD | 6.22% |
| 2014 FY | 134.8 Million USD | -1.39% |
| 2014 Q4 | 134.8 Million USD | -19.43% |
| 2014 Q3 | 167.3 Million USD | 9.63% |
| 2013 Q4 | 136.7 Million USD | 0.0% |
| 2013 FY | 136.7 Million USD | 4.83% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 130.4 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 581.38 Million USD | 1.27% |
| Bausch Health Companies Inc. | 1.54 Billion USD | 62.824% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -74.521% |
| Elanco Animal Health Incorporated | 1.73 Billion USD | 66.916% |
| Perrigo Company plc | 1.14 Billion USD | 49.689% |
| Teva Pharmaceutical Industries Limited | 4.02 Billion USD | 85.725% |
| Zoetis Inc. | 2.56 Billion USD | 77.613% |